OTCMKTS:RZLTD Rezolute (RZLTD) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free RZLTD Stock Alerts $2.60 -0.29 (-10.03%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$2.50▼$2.8950-Day Range$1.21▼$3.5452-Week Range$16.00▼$24.05Volume455,095 shsAverage Volume4,788 shsMarket Capitalization$21.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Rezolute alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About RezoluteRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.Read More RZLTD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RZLTD Stock News HeadlinesNovember 9, 2023 | investing.comRezolute (RZLT) Earnings Dates & ReportsSeptember 3, 2023 | investing.comXilio Development Inc (XLO)April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.August 9, 2023 | forbes.comSystems Ltd.June 1, 2023 | benzinga.comStonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye DiseaseMay 15, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Jazz Pharmaceuticals (JAZZ)May 12, 2023 | finanznachrichten.deRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company ProgressMay 11, 2023 | finance.yahoo.comRezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company ProgressApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.April 25, 2023 | finance.yahoo.comGreat news for Rezolute, Inc. (NASDAQ:RZLT): Insiders acquired stock in large numbers last yearMarch 28, 2023 | markets.businessinsider.comRezolute (RZLT) Gets a Buy from H.C. WainwrightFebruary 12, 2023 | finanznachrichten.deRezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company ProgressFebruary 10, 2023 | finance.yahoo.comRezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company ProgressFebruary 7, 2023 | benzinga.comXeris Biopharma Holdings Stock (NASDAQ:XERS), Quotes and News SummaryFebruary 2, 2023 | finance.yahoo.comAfter losing 37% in the past year, Rezolute, Inc. (NASDAQ:RZLT) institutional owners must be relieved by the recent gainNovember 10, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and Rezolute (RZLT)November 1, 2022 | technews.tmcnet.comRezolute to Present at the Jefferies London Healthcare ConferenceSee More Headlines Receive RZLTD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:RZLTD CUSIPN/A CIKN/A Webwww.rezolutebio.com Phone650 206 4507FaxN/AEmployees23Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-153.46% Return on Assets-111.71% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio3.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book2.10Miscellaneous Outstanding Shares8,418,000Free FloatN/AMarket Cap$21.89 million OptionableNot Optionable Beta4.63 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Nevan Charles Elam (Age 53)CEO & Director Comp: $869.45kDr. Keith A. Vendola M.B.A. (Age 48)M.D., MBA, Chief Financial Officer Comp: $422.76kDr. Sankaram Mantripragada (Age 60)Chief Scientific Officer Comp: $620.76kMr. Michael R. DeperroHead of OperationsDr. Brian RobertsHead of Clinical Devel.Ms. Paula OpalHead of RegulatoryDr. Sharon Xueyan WangHead of Preclinical Devel.More ExecutivesKey CompetitorsSpruce BiosciencesNASDAQ:SPRBIntelGenx TechnologiesOTCMKTS:IGXTAprea TherapeuticsNASDAQ:APRENRx PharmaceuticalsNASDAQ:NRXPLexaria BioscienceNASDAQ:LEXXView All Competitors RZLTD Stock Analysis - Frequently Asked Questions How have RZLTD shares performed in 2024? Rezolute's stock was trading at $0.9925 at the beginning of 2024. Since then, RZLTD shares have increased by 162.0% and is now trading at $2.60. View the best growth stocks for 2024 here. How do I buy shares of Rezolute? Shares of RZLTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RZLTD) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
